Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2022 23:39 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

愛科百發在第12屆國際呼吸道合胞病毒（RSV）年會上報告了愛司韋™在RSV感染的住院嬰幼兒中的三期臨床試驗（AIRFLO）積極結果

中國上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
October 06, 2022 23:39 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

爱科百发在第12届国际呼吸道合胞病毒（RSV）年会上报告了爱司韦™在RSV感染的住院婴幼儿中的三期临床试验（AIRFLO）积极结果

中国上海, Oct. 07, 2022 (GLOBE NEWSWIRE) --...
October 06, 2022 23:39 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium

SHANGHAI, China, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Results from Shanghai Ark Biopharmaceutical Co., Ltd. (Ark Biopharmaceutical)’s successful Phase 3 study (AIRFLO) with the respiratory syncytial...
January 25, 2022 05:06 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

爱科百发宣布完成抗呼吸道合胞病毒新药齐瑞索韦的III期临床试验全部患者入组和用药治疗

SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) --...
January 25, 2022 05:06 ET | Source: Shanghai Ark Biopharmaceutical Co., Ltd.

ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection

SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...